Compare LCLN & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCLN | WVE |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.7M | 673.9M |
| IPO Year | 2026 | 2015 |
| Metric | LCLN | WVE |
|---|---|---|
| Price | $23.67 | $3.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 21 |
| Target Price | ★ $27.07 | $17.22 |
| AVG Volume (30 Days) | 342.2K | ★ 2.9M |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | $28.20 | $19.15 |
| Revenue Next Year | $15.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $20.05 | $3.04 |
| 52 Week High | $27.55 | $21.73 |
| Indicator | LCLN | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 32.54 |
| Support Level | $22.81 | $3.04 |
| Resistance Level | $23.75 | $4.07 |
| Average True Range (ATR) | 0.87 | 0.17 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 24.10 | 18.72 |
Lincoln International Inc is an independent investment banking advisory company focused on private capital markets. The company operates its business through its two operating segments: Investment Banking Advisory and Valuations and Opinions. The Investment Banking Advisory segment offers a range of services related to mergers and acquisitions, with key areas of focus including sell-side advisory, buy-side advisory, asset sales and divestitures, restructuring, primary and secondary capital raising, and merger-related engagements. The Valuations and Opinions segment provides valuation services to investment funds and financial institutions. The majority of revenue is derived from the Investment Banking Advisory segment. Geographically, the maximum revenue is derived from the Americas.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.